• Primary hypercholesterolaemia and mixed dyslipidaemia1

    • PRALUENT is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet :
      • in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or
      • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant or for whom a statin is contraindicated

    Established atherosclerotic cardiovascular disease1

    • PRALUENT is indicated in adults with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering LDL-C levels as an adjunct to correction of other risk factors :
      • in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies, or
      • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant or for whom a statin is contraindicated

    PRALUENT

    ADDITIONAL STUDIES

    Learn more

    PRALUENT DOSING

    Learn more
    1. Praluent Summary of Product Characteristics. Available at https://www.medicines.org.uk/emc/medicine/30956. Accessed December 2019.